Shuanghuanglian' formula creates new immune health products
Recently, CV Sciences, which specializes in hemp CBD products, announced that it will launch a herbal immune product CV Acute, which will be the company's first immune series of dietary supplements. The company said that such non-CBD products will be sold in more sales channels, including major e-commerce retailers who have not been exposed to CBD products before.
CV Acute contains a branded ingredient called V871 SHL, which is a proprietary formula based on traditional Chinese medicine "Shuanghuanglian" Chinese herbal products. Shuanghuanglian was developed as a combination in the 1960s, although the individual herbs in it have been used in traditional Chinese medicine for centuries. V871 SHL contains extracts of honeysuckle (Japanese honeysuckle), scutellaria root (often called Chinese scutellaria) and forsythia fruit extract.
Animal and in vitro studies have shown antiviral and inflammation-regulating properties. A large number of peer-reviewed clinical trials have shown that the formula is effective in reducing symptoms of respiratory diseases. Clinical trials have shown that there are some health benefits in human trials that significantly reduce the duration of the common cold and bronchitis without any adverse events or toxic reactions.
A review article published in the "International Journal of Biological Sciences" studied the efficacy of Shuanghuanglian and several other Chinese herbal formulas in reducing some respiratory infections in animal, in vitro and human studies. This includes a very preliminary study to evaluate the interaction between the formula and infected COVID-19 cells in an in vitro environment. This formula can "potentially inhibit" a series of cytokines and chemokines, although no clinical trials have been published for humans.
The company has considered adding CBD to the formula, but doing so will prevent the supplement from entering more commercial platforms. CV Acute represents a strategic category expansion and a natural evolution of CV Sciences' positioning as a leading health company. This product is considered a safe plant formula for maintaining immunity and respiratory health. This is particularly important because many retailers are not yet able to provide CBD products that have proven to support the immune system, and may consider adding CBD to their formulas in the future.
Looking for chemical products? Let suppliers reach out to you!
2026-07-18
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Lilly’s Indiana Investment Puts API Capacity at the Center of Obesity Drug Competition
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
BASF’s Price Increase Shows Pharma Excipients Are Still Exposed to Chemical Cost Pressure
-
Betting on Next-Generation Metabolic Therapies: Pfizer’s Big Wager on Metsera and Its Strategic Reshaping in China
-
Small Pharma Firms Under Threat as Regulator Tightens Quality Norms
-
Merck Nears Acquisition of Cidara to Strengthen Flu Prevention Arsenal
-
Biocon Weighs Merger of Biocon Biologics to Unlock Value
-
Sun Pharma’s Utreglutide Shows Promising Weight Loss and Liver Fat Reduction
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
The GLP-1 Sweet Shot in India’s Diabetic Gut
Recommend Reading
-
Parliamentary Panel Urges Expanded Price Controls as Dozens of Cancer Drugs Remain Unregulated
-
Glenmark Recalls Over 110000 Bottles of BP and COPD Drugs in US Due to Safety Concerns
-
Novo Nordisk Reports Theft of Six Drug Batches in India Authorities Warn of Severe Patient Safety Risks
-
Sun Pharma’s Secret Sauce: Solve the Specific, Win the Market
-
The Oral GLP-1 Cage Match: Orforglipron vs Rybelsus
-
DKSH to Distribute Exsymol's Silanols, Peptides, and Natural Active Ingredients in South Korea
-
Premium Global Chemical Sourcing Requests (12 - 16 Mar, 2026)
-
Strait of Hormuz Reopens, Oil Prices Plunge: Is the Chemical Price Rally Over?
-
China Is Finally Moving on Petrochemical Plants, and This Time Low-Efficiency Capacity Really Is Being Forced Out
-
India Removes Import Tax on 40 Petrochemical Products